Vis enkel innførsel

dc.contributor.authorHopland-Nechita, Florin Vasile
dc.contributor.authorAndersen, John Roger
dc.contributor.authorRajalahti, Tarja
dc.contributor.authorAndreassen, Trygve
dc.contributor.authorBeisland, Christian
dc.date.accessioned2023-10-26T08:56:55Z
dc.date.available2023-10-26T08:56:55Z
dc.date.created2023-09-22T10:55:34Z
dc.date.issued2023
dc.identifier.citationMetabolomics. 2023, 19 (9), .en_US
dc.identifier.issn1573-3882
dc.identifier.urihttps://hdl.handle.net/11250/3098868
dc.description.abstractIntroduction The objective of this study was to explore potential novel biomarkers for moderate to severe lower urinary tract symptoms (LUTS) using a metabolomics-based approach, and statistical methods with significant different features than previous reported. Materials and Methods The patients and the controls were selected to participate in the study according to inclusion/exclusion criteria (n = 82). We recorded the following variables: International prostatic symptom score (IPSS), prostate volume, comorbidities, PSA, height, weight, triglycerides, glycemia, HDL cholesterol, and blood pressure. The study of 41 plasma metabolites was done using the nuclear magnetic resonance spectroscopy technique. First, the correlations between the metabolites and the IPSS were done using Pearson. Second, significant biomarkers of LUTS from metabolites were further analysed using a multiple linear regression model. Finally, we validated the findings using partial least square regression (PLS). Results Small to moderate correlations were found between IPSS and methionine (-0.301), threonine (-0.320), lactic acid (0.294), pyruvic acid (0.207) and 2-aminobutyric-acid (0.229). The multiple linear regression model revealed that only threonine (p = 0.022) was significantly associated with IPSS, whereas methionine (p = 0.103), lactic acid (p = 0.093), pyruvic acid (p = 0.847) and 2-aminobutyric-acid (p = 0.244) lost their significance. However, all metabolites lost their significance in the PLS model. Conclusion When using the robust PLS-regression method, none of the metabolites in our analysis had a significant association with lower urinary tract symptoms. This highlights the importance of using appropriate statistical methods when exploring new biomarkers in urology.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleIdentifying possible biomarkers of lower urinary tract symptoms using metabolomics and partial least square regressionen_US
dc.title.alternativeIdentifying possible biomarkers of lower urinary tract symptoms using metabolomics and partial least square regressionen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume19en_US
dc.source.journalMetabolomicsen_US
dc.source.issue9en_US
dc.identifier.doi10.1007/s11306-023-02046-2
dc.identifier.cristin2177843
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal